Lilly to lift lid on data for prize ARMO I-O asset at ESMO 2018

10 October 2018
2019_biotech_test_vial_discovery_big

At the upcoming congress of the European Society for Medical Oncology (ESMO), Eli Lilly (NYSE: LLY) will present a range of new data, including on the investigational compound pegilodecakin.

Lilly picked up pegilodecakin through its $1.6 billion all-cash acquisition of California’s ARMO BioSciences earlier this year, part of a strategic move to make waves in the immuno-oncology space.

Pegilodecakin is a PEGylated interleukin (IL)-10 which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology